CompletedPhase 3NCT00079833
Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome
Studying Zollinger-Ellison syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AstraZeneca
- Principal Investigator
- Nexium Medical Science Director, MDAstraZeneca
- Intervention
- Esomeprazole magnesium (Nexium)(drug)
- Enrollment
- 25 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2003 – 2005
Study locations (8)
- Research Site, Los Angeles, California, United States
- Research Site, Gainesville, Florida, United States
- Research Site, Columbus, Ohio, United States
- Research Site, King of Prussia, Pennsylvania, United States
- Research Site, Philadelphia, Pennsylvania, United States
- Research Site, Clichy, France
- Research Site, Paris, France
- Research Site, Saint-Germain-en-Laye, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00079833 on ClinicalTrials.govOther trials for Zollinger-Ellison syndrome
Additional recruiting or active studies for the same condition.